MedDataX Logo

Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients

NCT ID: NCT02858414

Last Updated: 2018-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-02

Study Completion Date

2017-10-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the impact of highly active antiretroviral therapy on the size of the latent viral reservoirs in resting CD4+ T cells and monocytes in HIV positive patients. The activation state of the cells will be assessed, by measuring the activation of Akt, to determine its influence on the size of the viral reservoirs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

NCT05215704

HIV Infections HIV-1-infection HIV-2 Infection
RECRUITING

123I Radiolabeled 3BNC117

NCT03468582

Human Immunodeficiency Virus
COMPLETED EARLY_PHASE1

Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection

NCT02588820

HIV Infections
UNKNOWN PHASE3

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

NCT01038401

HIV Infection
COMPLETED NA

Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses

NCT05219916

Human Immunodeficiency Virus I Infection
TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

blood sample

Group Type EXPERIMENTAL

additional blood sample

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

additional blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infected patients under Highly Active Anti-Retroviral Therapy (HAART) or Naïve from treatment

Exclusion Criteria

* Age limits
* Pregnancy
* Legal restrictions to consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Georges HERBEIN, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Besancon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Régional Universitaire

Besançon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P/2014/223

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
NCT01541085 COMPLETED
Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation
NCT02557997 UNKNOWN
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
NCT00807443 COMPLETED PHASE2
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT00966160 COMPLETED PHASE3
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir
NCT04741100 WITHDRAWN
Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort
NCT00989144 COMPLETED
Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men
NCT02526940 COMPLETED
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558 COMPLETED PHASE2
Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir
NCT06640192 RECRUITING PHASE2
Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects
NCT01024556 COMPLETED
LoViReT (Low Viral Reservoir Treated Patients)
NCT02972931 COMPLETED
Effect of Dolutegravir Intensification on HIV-1 Reservoirs
NCT05351684 COMPLETED PHASE2
A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
NCT01571466 COMPLETED PHASE1
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384 RECRUITING PHASE1
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
NCT02733419 COMPLETED PHASE3
Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults
NCT00343941 COMPLETED PHASE2
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
NCT02471430 COMPLETED PHASE1/PHASE2
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
NCT04448158 COMPLETED
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 RECRUITING
ANRS 12406 EvvA Study
NCT04593979 UNKNOWN
Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
NCT06441123 RECRUITING
The Use of Leukapheresis to Support HIV Pathogenesis Studies
NCT01161199 RECRUITING
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
NCT02926456 COMPLETED
Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
NCT02384967 COMPLETED PHASE2
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
NCT05584397 ENROLLING_BY_INVITATION